INHIBITION OF INTERLEUKIN 6 IN IMMUNE INFLAMMATORY RHEUMATIC DISEASES: ACHIEVEMENTS, PROSPECTS, AND HOPES
Much attention has been recently paid to the study of interleukin 6 (IL-6) among the cytokines involved in the development of immune inflammatory rheumatic diseases (IIRDs). The introduction of monoclonal antibodies that inhibit the activity of IL-6 (tocilizumab, TCZ) in clinical practice in 2010 is...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Russo |
| Gepubliceerd in: |
IMA PRESS LLC
2018-01-01
|
| Reeks: | Научно-практическая ревматология |
| Onderwerpen: | |
| Online toegang: | https://rsp.mediar-press.net/rsp/article/view/2461 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|